EV Group Strengthens Its European Presence With the Acquisition of Cornelius Polska
22.1.2026 13:19:00 CET | Business Wire | Press Release
Eigenmann & Veronelli Group (“EV Group”), a leading distributor and manufacturer of specialty chemicals and food ingredients, has signed an agreement to acquire the majority shareholding in Cornelius Polska.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122961168/en/
Photographed (left to right): Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Piotr Wasilewski, General Manager, Cornelius Polska Sp. z. o. o.; Cristina Colombo, Chief Financial Officer, EV Group; Dr Neville Prior, Group Chairman, Cornelius Group plc; Gabriele Bonomi, Chief Executive Officer, EV Group
Established in Poland in 2007 and headquartered in Warsaw, Poland, Cornelius Polska is a well‑established distributor of specialty chemicals, serving as a key partner to international suppliers, and a broad and diverse customer base. With operations firmly rooted in Poland, the company is active in the beauty & personal care, food, and several industrial markets.
With a comprehensive premium product portfolio and a highly skilled team of approximately 28 people, Cornelius Polska is recognized for its technical expertise, long‑standing relationships, and strong commercial capabilities. In 2025, the company reported annual revenues of around EUR 16 million.
This acquisition represents a highly strategic step for EV Group, enhancing the Group’s scale and strengthening its presence across Europe. It also unlocks new growth potential and strategic opportunities in the beauty and personal care, food, and industrial markets.
“This is an important milestone in expanding our footprint in Europe,” said Gabriele Bonomi, CEO of EV Group. “Cornelius Polska brings deep local market knowledge, a loyal customer base, and a strong platform for growth across multiple applications, making it a real asset for our partners, teams, and suppliers across Europe. We are also pleased to welcome a highly experienced and skilled team that will add significant value to our organization and ensure continuity in established customer and supplier relationships.”
Dr. Neville Prior, Chairman of the Cornelius Group, said: “Cornelius Polska has been an important part of our organisation for many years, and we are extremely proud of what the team has accomplished. Joining EV Group creates new opportunities for both the business and its people, and I am confident this transition will deliver lasting value for customers and partners.”
The transaction is subject to customary regulatory approvals and closing conditions, and completion is expected in the first quarter of 2026.
EVGROUP
Founded in 1910, Eigenmann & Veronelli Group is an international solutions provider of specialty chemicals and food ingredients. Headquartered in Pero, Italy, EV has a direct presence in Italy, Iberia, Turkey, and the U.A.E. and a commercial reach in more than 45 countries. In 2025, EV generated a consolidated turnover of 340 million euros with more than 350 employees. With over a century of experience, EV is synonymous with effectiveness and efficiency, combining local market knowledge with chemical innovations, and offering a high-quality and diversified portfolio of specialty chemicals and food ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, and comprehensive regulatory know-how for a wide range of industries.
Follow us on LinkedIn
CORNELIUS GROUP
Cornelius Group is an independent manufacturer and distributor of raw materials, ingredients and specialty chemicals for life science, performance chemicals and ocular sector operating in UK, Europe, Asia and USA. The core business values: We Lead, We Care, We Deliver are at the heart of the vision, strategy and everyday thinking to deliver differentiated outcomes for both customers and business partners. Cornelius has an active membership to the UN Global Compact, ISO accredited for Quality Management (9001:2015), Environmental Management Systems (14001:2015) and Occupational Health and Safety Management (45001).
Follow us on LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20260122961168/en/
Contacts
Press Contacts
For further enquiries, please contact:
Federica Urso
Corporate Communications Director, EV Group
Mob. (+39) 338 7295116
@: mediarelations@eigver.it
Miriam Bolzoni
PR & Media Relations, EV Group
@: mediarelations@eigver.it
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom